The high cost of drug development is forcing companies to think differently about how to best carry discoveries through to
the marketplace. Companies are turning to collaborative alliances that call for the sharing of data and resources, entering
into partnerships with academic and nonprofits, and working with government agencies to speed translational research, all
in hopes of forging new models to reduce the risks and costs of early-stage research.
G. Steven Burrill
Such partnerships have increased at the same time that traditional corporate alliances—at least those with disclosed deal
values—have declined. There were just $432 million in corporate alliances announced in May 2012, down from $3 billion for
the same period a year ago, with no single deal valued at more than $100 million. It was by far the lowest level of activity
since Burrill & Company began tracking the data monthly in 2009. Year-to-date, the value of disclosed US partnerships is down
37% compared with the same period a year ago, with just less than $7 billion in activity. Global partnering activity has fallen
18% year-to-date, with $12.5 billion in disclosed deals.
Although this decrease in disclosed deal values does not necessarily reflect less activity, it seems to signal a trend among
companies that are tapping into a wide variety of resources to access new potential therapeutics as well as new ways to fund
Indicative of the trend is the $285-million effort announced in May 2012 to develop new antibiotics to combat the growing
problem of drug-resistant microbes, an area most biopharmaceutical companies have abandoned because the scientific challenges
and complex regulatory requirements have made it financially unviable.
The new collaboration involves five European pharmaceutical companies—GlaxoSmithKline, AstraZeneca, Sanofi, Janssen, and Basilea
Pharmaceutica—working with researchers at leading academic institutions. It is the first such effort under the European Commission's
Action Plan, announced in November 2011, to address the rising threats from drug-resistant bugs.
The collaboration is also part of Europe's Innovative Medicines Initiative, the world's largest public-private partnership
in healthcare, which seeks to improve the environment for pharmaceutical innovation in Europe by engaging and supporting networks
of industrial and academic experts in collaborative research projects. The research program will initially focus on sharing
information, supporting potential antibiotics already in the pipeline through new research, improving clinical trial design,
and continuing research and discovery of new antibiotics.
The Innovative Medicines Initiative has issued a call for proposals in an effort to engage multiple public partners throughout
Europe. The antimicrobials program is initially budgeted with $285 million (€223.7 million), with $137 million (€109 million)
of initiative funding and contributions of $148 million (€114.7 million) of in-kind contributions by the participating pharmaceutical
Until recently, most drugmakers were protective of their intellectual property, working in a silo-like atmosphere to develop
new drugs. But as the costs of drug development have skyrocketed and drugmakers' blockbuster drugs have begun to lose patent
protection, the usual way of doing business is no longer viable.
Consider Bristol-Myers Squibb,
which has created a new Inter-national Immuno-Oncology Network. The network includes industry, universities, and research
centers from around the world working together to advance scientific understanding of the human immune system's potential
to fight cancer. Bristol-Myers Squibb, which already has a large oncology portfolio, has been making a big push towards cancer
Ten academic or cancer-research institutions from around the world including The Netherlands Cancer Institute, Dana-Farber
Cancer Institute, The Royal Marsden NHS Foundation Trust, the Institute of Cancer Research, and Johns Hopkins Kimmel Cancer
Center are joining Bristol-Myers Squibb in the collaborative effort.
The public-private partnerships formed through the collaboration aim to leverage the intellectual capabilities of an extensive
global network with the ultimate goal of translating the research into new models for drug discovery and development, and
eventually into new, improved cancer therapies.